"Medical Speed Reading Agency" Beijing yesterday tested 76,499 people Diri kit to obtain the record certificate

Beijing tested 76,499 people yesterday positive 59; Tianshili Biology will be listed; Baiji Shenzhou BTK inhibitor Zebtini the first prescription landing in the country; Changxi Pharmaceuticals completed 80 million yuan B round financing; Beida Pharmaceuticals Bevalju semazumab injection listing permit application was accepted; Roche TIGIT inhibitor, VEGF/ Ang2 double clinical application in China ..On the 14th, a total of 76,499 people were tested by the city's nucleic acid testing facility in Beijing, with 59 positive cases, of which 27 cases were reported in the Ditan Hospital, 21 new confirmed cases were added, and 11 positive tests were to be diagnosed(Xinhua) --Beijing Daily has learned that the current market of epidemic prevention materials are adequately supplied, large chain pharmacies and e-commerce platform supply is stable, the public do not need to be nervous to hoard goods(Beijing Daily)still serves as a director of the company on the 14th, Xinbang Pharmaceuticals issued a notice that the company's board of directors on June 13, 2020 received the company's director, deputy general manager, MsXu Qi submitted a written resignation reportMsXu Qi applied to resign as deputy general manager of the company for personal work reasonsAfter resigning as deputy general manager, he remained a director of the company(Sina Pharmaceutical News)TianShili 13 issued a notice that Tianshili Pharmaceutical Group intends to spin off its subsidiaries to the Shanghai Stock Exchange, the company listed(Tianshili Announcement)domestic focus on inhalation drug delivery system platform company Changxi Pharmaceutical announced the completion of 80 million yuan B round of financingThe current round of financing is funded by a Magenta Pharmaceutical subsidiary, a magenta pharmaceutical company and other companies, the funds will be used to Changxi Pharmaceuticals to promote clinical research in research projects, enrich the research and development team and expand the research and development pipeline(Sina Pharmaceutical News)15, Baiji Shenzhou independent research and development of a new generation of BTK inhibitor Bai Yueze (universal name: Zebutini capsule) officially began to supply drugs to hospitals and pharmacies across the country, and in Suzhou University affiliated with the first hospital issued the first prescription, which is only 12 days after the drug was approved in China (Pharmaceutical MingKang) Dire Medical issued a notice that the company's nucleic acid extraction kit (magnetic bead sinuse method) recently obtained by the Changchun Municipal Market Supervision Bureau issued a "first category of medical device filing certificate." (Dire Medical Announcement) Beida Pharmaceuticals issued a notice that, recently, the company received the State Drug Administration issued a "acceptance notice" (acceptance number: CXSS200027), the company declared the Bevalju sing-singofa injection for advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer patients on the market license application has been accepted by the State Drug Administration (Sina Pharmaceutical News) at the 25th annual meeting of the European Society of Hematology, Johnson and Johnson's Janssen Pharmaceuticals announced a darzalex three-phase trial data called ANDROMEDA The trial was conducted in newly diagnosed al-type amyloid degeneration patients to assess the safety and effectiveness of Darzalex Faspro combined cyclophosphamide, boratizomi and dexamethasone compared to CyBorD The results showed that Darzalex Faspro combination therapy reached the main endpoint of hematology total remission rate (Sina Pharmaceutical News) Roche's Genetek has released positive data on two years of treatment for patients with type 2-2 or type 3 chiropractic atrophy in part 1 of SUNFISH The results of the exploratory efficacy analysis showed that the movement function of patients was significantly improved after 24 months of risdiplam treatment compared to natural history data (Sina Pharmaceutical News) Roche submitted four applications for new clinical trials in China for the new drug tiragolumab injection and faricimab injection, which were accepted on the 13th Tiragolumab is a key research TIGIT inhibitor developed by Roche, faricimab, a bispecific antibody that targets both VEGF and Ang2 At present, both drugs have entered the clinical phase of Phase 3 in the world (Pharmaceutical Mingcond) AstraZeneca recently announced the detailed results of the Phase II single-arm ACE-CL-001 trial for the treatment of patients with chronic lymphocytic leukemia (CLL) with the first-line single drug, Calquance, as well as long-term efficacy and tolerance data for The Treatment of Patients with Relapsed or Incurable CLL Phase III ASCEND The results showed that the total remission rate of 4 years in patients with cLL in the first-line treatment of Calquance single-drug treatment was as high as 97%, and the survival rate of patients with relapse/difficult CLL was as high as 88% for 18 months, and showed good long-term safety (Biological Valley) recently announced the results of a Phase II clinical trial of insulin icodec, a long-acting, long-acting underlying insulin, at the 80th Scientific Meeting of the American Diabetes Association The data showed that in adults with type 2 diabetes, insulin icodec had similar blood sugar control and similar safety when it came with insulin glargine products once a day (Sina Pharmaceutical News) Novo Nordisk recently announced the top-line results of the last two Phase IIIa clinical trials (STEP 2, STEP 3) in the StepII Phase III STEP project of Somarupeptide Weight Loss Effect III The STEP 2 trial was conducted in adult patients with type 2 diabetes and obesity/overweight, and the STEP 3 trial was conducted in obese or overweight adult patients with comorbidities, with somarutide as an auxiliary therapy for intensive behavioral therapy The results showed that a 2.4 mg dose of subcutaneous injection of somarutide per week resulted in a statistically significant reduction in weight compared to comfort (Bio Valley) diabetes! Lilly Trulicity's efficacy beats Somarutide and essenatide
Lilly recently presented a new real-world study at the 80th American Diabetes Association Scientific Conference, showing that trulicity has significantly higher compliance and longer persistence than one weekly injection of somarutide or esenatide (BioValley) Wanchun Pharmaceuticals announced that its "first-in-class" new drug Punabring was used in a phase 3 clinical trial of CHEM-induced severe neutrophilocytic disease, WHICH has reached the main end of the study The medium-term significant results of the study are the first breakthrough in the treatment criteria and clinical benefits of CIN indications in 30 years (Pharmaceutical Mission)